newsfilter
← Earnings
Earnings Releases·

Vycor Medical — Three and Nine Months Ended September 30, 2026 Earnings Summary

  • Financial Performance:

    • Total revenue for the three months ended September 30, 2026, was $414,895, a 19% decrease from $513,792 in the same period in 2025.
    • Total revenue for the nine months ended September 30, 2026, was $1,291,699, an 11% decrease from $1,446,523 in the same period in 2025.
    • Vycor Medical division revenue decreased 18% to $402,048 for the three months ended September 30, 2026 (vs. $492,102 in 2025) and 11% to $1,243,713 for the nine months ended September 30, 2026 (vs. $1,392,410 in 2025).
    • NovaVision division revenue increased 41% to $12,847 for the three months ended September 30, 2026 (vs. $21,690 in 2025) and 11% to $47,986 for the nine months ended September 30, 2026 (vs. $54,113 in 2025).
    • Gross profit for the three months ended September 30, 2026, was $353,017 (85% margin), a 22% decrease from $451,932 (88% margin) in 2025.
    • Gross profit for the nine months ended September 30, 2026, was $1,072,615 (83% margin), a 12% decrease from $1,225,737 (85% margin) in 2025.
    • GAAP operating profit for the three months ended September 30, 2026, was $27,424, compared to $32,085 in 2025.
    • GAAP operating profit for the nine months ended September 30, 2026, was $80,083, compared to $70,425 in 2025.
    • Non-GAAP operating profit for the three months ended September 30, 2026, was $43,011, compared to $60,162 in 2025.
    • Non-GAAP operating profit for the nine months ended September 30, 2026, was $125,751, compared to $166,262 in 2025.
    • GAAP net loss available to common stockholders for the three months ended September 30, 2026, was $(161,447) or $(0.00) per share, compared to $(157,249) or $(0.00) per share in 2025.
    • GAAP net loss available to common stockholders for the nine months ended September 30, 2026, was $(325,812) or $(0.01) per share, compared to $(334,110) or $(0.01) per share in 2025.
    • Non-GAAP net loss available to common stockholders for the three months ended September 30, 2026, was $(145,860) or $(0.00) per share, compared to $(129,172) or $(0.00) per share in 2025.
    • Non-GAAP net loss available to common stockholders for the nine months ended September 30, 2026, was $(280,144) or $(0.01) per share, compared to $(238,273) or $(0.01) per share in 2025.
    • Non-GAAP cash operating expenses for the three months ended September 30, 2026, were $310,006, compared to $391,770 in 2025.
    • Non-GAAP cash operating expenses for the nine months ended September 30, 2026, were $946,864, compared to $1,059,475 in 2025.
    • Preferred stock dividends were $(162,185) for the three months ended September 30, 2026, and $(324,370) for the nine months ended September 30, 2026.
    • Interest expense related to a related party was $(12,573) for the three months and $(37,713) for the nine months ended September 30, 2026.
  • Business Segments and Product Lines:

    • The Vycor Medical division produces the ViewSite™ Brain Access System (VBAS), a minimally invasive neurosurgical device used in over 350 US hospitals and internationally.
    • The NovaVision division offers therapy programs for visual disorders after stroke or brain injury, including Visual Restoration Therapy (VRT) and the NeuroEyeCoach program, and remains in development.
    • During 2026 to date, four new peer-reviewed studies were published on VBAS, bringing the total to 54 published clinical papers, with an additional 14 other clinical papers.
    • New studies highlighted VBAS effectiveness in complex pediatric tumor resection, fewer new neurological deficits compared to traditional blade retractors in tumor resection, effective decompression of posterior fossa metastases, and stable corridors for intracerebral hemorrhage evacuation in Japan.
    • VBAS is protected by 49 issued and 8 pending patents.
  • Other Key Points:

    • The decrease in US sales for the Vycor Medical division in 2026 is attributed to higher than normal sales in 2025 from new hospitals and bulk orders from existing hospitals.
    • International sales for the Vycor Medical division increased during the three-month period but decreased slightly over the nine-month period; international sales are described as "lumpy" with large orders sometimes falling in different quarters.
    • The company reported a loss from discontinued operations, net of tax, of $(783) for the three months and $(3,949) for the nine months ended September 30, 2026.
    • Weighted average number of shares outstanding remained constant at 33,372,796 for both the three and nine-month periods in 2026 and 2025.
    • The company operates under the OTCQB ticker symbol VYCO.